Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

ENDRA Life Sciences (NDRA) EBIAT (2016 - 2025)

ENDRA Life Sciences has reported EBIAT over the past 6 years, most recently at -$3.1 million for Q4 2021.

  • Quarterly EBIAT fell 37.94% to -$3.1 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$11.2 million through Dec 2021, up 4.22% year-over-year, with the annual reading at -$7.0 million for FY2025, 38.93% up from the prior year.
  • EBIAT was -$3.1 million for Q4 2021 at ENDRA Life Sciences, down from -$2.7 million in the prior quarter.
  • Over five years, EBIAT peaked at -$741623.0 in Q1 2017 and troughed at -$4.8 million in Q4 2019.
  • The 5-year median for EBIAT is -$2.7 million (2019), against an average of -$2.6 million.
  • Year-over-year, EBIAT plummeted 280.96% in 2018 and then soared 53.2% in 2020.
  • A 5-year view of EBIAT shows it stood at -$2.3 million in 2017, then decreased by 3.09% to -$2.4 million in 2018, then crashed by 103.3% to -$4.8 million in 2019, then soared by 53.2% to -$2.3 million in 2020, then tumbled by 37.94% to -$3.1 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's EBIAT are -$3.1 million (Q4 2021), -$2.7 million (Q3 2021), and -$3.2 million (Q2 2021).